Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti–programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHO...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Ferris, R.L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Harrington, K., Kasper, S., Vokes, E.E., Even, C., Worden, F., Saba, N.F., Iglesias Docampo, L.C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W.J., Kopit, J., Shaw, J.W., Gillison, M.L.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564292/
https://ncbi.nlm.nih.gov/pubmed/27718784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1602252
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料